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Hematopoietic stem cell transplantation (HCT) is used to treat patients with blood cell malignancies. 
Before receiving a transplant, patients first must undergo treatment regimens to remove diseased 
bone marrow and to create an immunosuppressive environment that allows engraftment of donor 
stem cells and reconstitution of a normal blood system. Although the outcomes for HCT have 
improved, graft-versus-host-disease (GVHD) and relapse of the malignancy remain the main causes 
of morbidity and mortality. GVHD results from transplanted donor immune cells recognizing recipient 
cells as foreign and attacking them, however these same donor immune cells can prevent relapse by 
attacking diseased cells. The most optimal immunosuppressive drug regimen that balances 
dampening the risk of GVHD while preventing relapse is still under investigation. In a phase II clinical 
trial report published inHaematologica, lead author and visiting investigator Dr. Brian Kornblit in the 
laboratory of Dr. Brenda Sandmaier of the Clinical Research Division reports the safe addition of 
sirolimus to the immunosuppressive regimen after transplant. 
Eleven different transplant centers treated patients prior to transplant with a reduced-intensity 
regimen, using low-dose total body irradiation and fludarabine, a cytotoxic purine nucleoside analog. 
This nonmyeloablative regimen allowed for the treatment of patients who cannot tolerate traditional 
high-dose conditioning regimens, such as older patients and those with comorbidities (Storb et al., 
2012). These reduced-intensity regimens promote engraftment through immunosuppression, but 
result in less tissue damage, inflammation, and lower rates of GVHD than traditional myeloablative 
regimens that aim to remove all diseased cells. After receiving transplants from unrelated matched 
donors, patients were randomized to three immunosuppressive drug regimens: arm 1, the standard 
regimen of tacrolimus and mycophenolate mofetil for 180 and 95 days respectively (n=69); arm 2, an 
experimental regimen of tacrolimus and mycophenolate mofetil for 150 and 180 days respectively 
(n=71), or arm 3, the same treatment as arm 2 with the addition of sirolimus for 80 days (n=68). 
 Both mycophenolate mofetil and tacrolimus are commonly used post-HCT, while sirolimus is 
traditionally used in solid organ transplants to prevent rejection. Each drug functions by inhibiting 
different pathways that control immune cell function. Mycophenolate mofetil blocks the growth of T 
and B cells by inhibiting a specific enzyme involved in recycling purine nucleotides for DNA  
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synthesis. Tacrolimus inhibits calcineurin, an enzyme necessary for activation of T cell function. 
Sirolimus inhibits the mTOR cell signaling pathway, blocking the response of immune cells to 
cytokines. 
 Patients in all three arms of the study sustained donor engraftment with no significant differences in 
relapse or overall survival rates. The non-relapse mortality at 2 years was comparable among the 
three arms at 26%, 23%, and 18% respectively. While toxicity rates were similar, the rate of acute 
GVHD at day 150 was 64%, 48%, and 47% for the three arms respectively (arm 3 vs. arm 1 hazard 
ratio 0.62, p= 0.04). Since the incidence of acute GVHD was lower, fewer steroids were 
administered to patients in arm 3 versus arm 2 and arm 1 (32% vs. 49% vs. 55%, p= 0.009). The 
rate of cytomegalovirus (CMV) reactivation was also lower in arm 3 (22%) versus arm 2 (47%) and 
arm 1 (22%). The mechanism of decreased viral reactivation by sirolimus is unknown, but could be 
due to either reduced steroid use or antiviral activity of the drug. Taken together, the study 
demonstrated that the combination of the three immunosuppressive drugs is safe and reduces post-
transplant complications. 
"This study, which tests a new combination of immunosuppressive drugs, lowers the risk of acute 
GVHD and thus, reducing the secondary complications of steroid treatment and infections such as 
CMV, which contribute to morbidity and mortality. This allows the curative approach of HCT to be 
applied to a bigger group of patients with hematologic malignant and nonmalignant disorders," 
according to Dr. Sandmaier. A phase III randomized trial is ongoing to further investigate the efficacy 
of sirolimus after nonmyeloablative-conditioned HCT. 
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Image provided by Dr. Brian Kornblit 
A phase II trial of immunosuppressive drug regimens 
after hematopoietic stem cell transplant 
demonstrates safety of sirolimus addition with 
reduced post-transplant complications of acute 
GVHD (top) and CMV reactivation (bottom). Patients 
were randomized to: arm 1, tacrolimus 180 days and 
mycophenolate mofetil 95 days (n=69); arm 2, 
tacrolimus 150 days and mycophenolate mofetil 180 
days (n=71), or arm 3, tacrolimus 150 days, 
mycophenolate mofetil 180 days, and sirolimus 80 
days (n=68). 
 
